Prof Stefan Barth – Evaluation of tumor associated antigens to optically label cutaneous basal cell carcinoma for surgical excision
Prof Stefan Barth
Title of the project
Evaluation of tumor associated antigens to optically label cutaneous basal cell carcinoma for surgical excision.
Basal cell carcinoma (BCC) is the most common skin cancer worldwide with the second highest incidence rates in South Africa after Australia. Mohs surgery is the most effective standard treatment to remove BCC. This is a time consuming, expensive procedure which takes generally 3-4 or more hours of treatment. By finding antibodies for specific immunophenotyping of BCC and further modifying them with an advanced recombinant SNAP-tag antibody labelling technology, this project aims to design and engineer highly specific optically-labelled diagnostics for basal cell carcinoma BCC, which finally should allow to significantly reduce the current costs of treatment.